Exploring High Growth Tech Stocks in the United States

The market in the United States has shown a flat performance over the last week but has risen by 22% over the past year, with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves focusing on companies that demonstrate strong potential for revenue expansion and innovation, aligning well with these promising market conditions.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Super Micro Computer	24.36%	24.28%	★★★★★★
Ardelyx	21.09%	55.29%	★★★★★★
AVITA Medical	33.20%	51.87%	★★★★★★
Bitdeer Technologies Group	51.56%	122.57%	★★★★★★
TG Therapeutics	29.48%	43.58%	★★★★★★
Alkami Technology	21.99%	102.65%	★★★★★★
Clene	61.16%	59.11%	★★★★★★
Alnylam Pharmaceuticals	21.62%	56.70%	★★★★★★
Travere Therapeutics	30.52%	61.89%	★★★★★★
Blueprint Medicines	23.52%	55.88%	★★★★★★

Click here to see the full list of 231 stocks from our US High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Red Cat Holdings (NasdaqCM:RCAT)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Red Cat Holdings, Inc., along with its subsidiaries, offers a range of products, services, and solutions to the drone industry in the United States and has a market cap of $785.58 million.

Operations: Red Cat Holdings generates revenue primarily from its enterprise segment, which contributed $16.47 million. The company focuses on providing specialized products and services within the U.S. drone industry.

Red Cat Holdings, a player in the burgeoning drone technology sector, is making strides with recent contracts totaling $518,000 for its Edge 130 drones from the U.S. Army National Guard and other government agencies. These drones are celebrated for their AI-driven surveillance capabilities and robust performance in critical missions. Despite a challenging financial period with a reported net loss of $13.33 million in Q2 2025, Red Cat's strategic alliances, such as the integration of Palladyne AI's software into its Teal drones for enhanced autonomous operations, underscore its commitment to innovation and market expansion. This aligns with an ambitious revenue growth forecast of 87.2% per year and an expected earnings growth of 106.1%, positioning it potentially as a future profitable entity within three years amidst volatile market conditions.

• Unlock comprehensive insights into our analysis of Red Cat Holdings stock in this health report.

• Examine Red Cat Holdings' past performance report to understand how it has performed in the past.

Invivyd (NasdaqGM:IVVD)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Invivyd, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States, with a market cap of $252.39 million.

Operations: The company focuses on developing and commercializing antibody-based treatments for infectious diseases. It operates within the biopharmaceutical sector in the United States, with a market capitalization of approximately $252.39 million.

Invivyd, a biotech firm specializing in monoclonal antibodies for COVID-19, is poised for rapid growth with its novel candidate VYD2311 showing promising Phase 1/2 trial results. Despite current unprofitability and a volatile share price, Invivyd's revenue is expected to grow at 43.6% annually, outpacing the U.S. market average of 8.8%. The company's strategic focus on high-potency antibodies could redefine treatment standards in immunocompromised populations, leveraging its robust R&D framework that continues to innovate against evolving viral strains.

• Dive into the specifics of Invivyd here with our thorough health report.

• Learn about Invivyd's historical performance.

ExlService Holdings (NasdaqGS:EXLS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: ExlService Holdings, Inc. is a company that provides data analytics and digital operations solutions both in the United States and internationally, with a market cap of $8.32 billion.

Operations: The company generates revenue through its key segments: Analytics ($770.51 million), Insurance ($591.10 million), Healthcare ($110.80 million), and Emerging Business ($298.59 million).

With a projected annual revenue growth of 11.6% and earnings expected to increase by 15% per year, ExlService Holdings (EXLS) is navigating the competitive landscape of professional services effectively. This growth is notably faster than the US market average of 8.8%, highlighting EXLS's robust operational framework despite not outpacing its industry peers in earnings growth over the past year, which stood at 6.7% compared to the industry's 10.6%. The company has also demonstrated a strong commitment to innovation with significant R&D investments, reinforcing its capacity for sustained growth and adaptation in a rapidly evolving sector. Moreover, EXLS’s Return on Equity is forecasted to reach an impressive 27.1% in three years, suggesting efficient management and promising financial health ahead.

• Click to explore a detailed breakdown of our findings in ExlService Holdings' health report.

• Gain insights into ExlService Holdings' historical performance by reviewing our past performance report.

Taking Advantage

• Take a closer look at our US High Growth Tech and AI Stocks list of 231 companies by clicking here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com